Published in J Virol on May 01, 2004
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol (2006) 2.94
Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol (2006) 2.79
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol (2006) 2.07
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther (2011) 2.04
Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol (2006) 1.97
Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors. Neuroscience (2009) 1.92
AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther (2005) 1.80
DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther (2008) 1.70
Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res (2007) 1.50
Recombinant adeno-associated virus transduction and integration. Mol Ther (2008) 1.44
Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther (2009) 1.42
Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol Ther (2005) 1.30
Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng (2008) 1.28
Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective. Hum Gene Ther (2015) 1.27
AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther (2010) 1.27
Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther (2010) 1.26
Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther (2005) 1.19
Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol (2012) 1.18
Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol (2011) 1.11
Self-complementary AAV2.5-BMP2-coated femoral allografts mediated superior bone healing versus live autografts in mice with equivalent biomechanics to unfractured femur. Mol Ther (2011) 1.10
Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther (2005) 1.05
Transgene expression in target-defined neuron populations mediated by retrograde infection with adeno-associated viral vectors. J Neurosci (2013) 1.02
Establishment of an AAV reverse infection-based array. PLoS One (2010) 0.94
Assembly of hybrid bacteriophage Qbeta virus-like particles. Biochemistry (2009) 0.91
Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum Gene Ther (2014) 0.91
E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal-Tailored Acceleration of AAV Evolution. Mol Ther (2015) 0.90
Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia. Hum Gene Ther (2006) 0.88
New vectors and strategies for cardiovascular gene therapy. Curr Gene Ther (2007) 0.87
Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy. Hum Gene Ther (2015) 0.87
Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation. Br J Haematol (2011) 0.86
Synthetic scaffold coating with adeno-associated virus encoding BMP2 to promote endogenous bone repair. Cell Tissue Res (2011) 0.83
Random Insertion of mCherry Into VP3 Domain of Adeno-associated Virus Yields Fluorescent Capsids With no Loss of Infectivity. Mol Ther Nucleic Acids (2012) 0.82
Adeno-associated Virus as a Mammalian DNA Vector. Microbiol Spectr (2015) 0.82
Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction. Hum Gene Ther (2012) 0.81
An adeno-associated viral vector transduces the rat hypothalamus and amygdala more efficient than a lentiviral vector. BMC Neurosci (2010) 0.81
Fast calcium sensor proteins for monitoring neural activity. Neurophotonics (2014) 0.81
High capsid-genome correlation facilitates creation of AAV libraries for directed evolution. Mol Ther (2015) 0.78
The neostriatum: two entities, one structure? Brain Struct Funct (2015) 0.78
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. Methods Mol Biol (2016) 0.77
Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes. Mol Genet Metab Rep (2015) 0.75
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 11.11
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76
Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol (1992) 6.16
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5.50
AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med (1999) 5.26
Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol (1998) 4.71
Gene therapy vectors based on adeno-associated virus type 1. J Virol (1999) 4.63
Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A (2000) 4.39
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A (2002) 4.30
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol (2000) 3.84
Cloning and characterization of adeno-associated virus type 5. J Virol (1999) 3.36
Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol (2000) 3.27
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol (2003) 3.25
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 3.15
Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol (2001) 3.11
Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol (2003) 2.93
Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol (1997) 2.91
Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol (2001) 2.56
Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol (1997) 2.31
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med (1999) 2.24
Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol (2000) 2.08
Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol (1999) 1.99
Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther (2001) 1.78
Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology (1999) 1.76
Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J Gen Virol (2000) 1.73
Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther (2002) 1.60
Generation and characterization of chimeric recombinant AAV vectors. Mol Ther (2003) 1.54
Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol (1999) 1.51
Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol (2001) 1.44
Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther (2001) 1.35
Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J Virol (2002) 1.35
Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol (2003) 1.29
RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther (2003) 1.27
Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5. J Biol Chem (2002) 1.27
Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. J Virol (2003) 1.24
Building a better vector: the manipulation of AAV virions. Virology (2000) 1.19
A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol Ther (2001) 1.10
Adenovirus and adeno-associated virus vectors. DNA Cell Biol (2002) 1.10
Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol (2002) 1.03
AAV-mediated gene transfer for hemophilia. Genet Med (2003) 0.88
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther (2006) 4.36
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Production and characterization of adeno-associated viral vectors. Nat Protoc (2006) 4.11
Investigation of the cause of death in a gene-therapy trial. N Engl J Med (2009) 3.02
Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther (2011) 2.91
Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med (2003) 2.70
Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol (2006) 2.63
The AAV vector toolkit: poised at the clinical crossroads. Mol Ther (2012) 2.53
Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet (2004) 2.36
Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med (2005) 2.10
Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol (2009) 2.07
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther (2011) 2.04
Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther (2011) 1.90
AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther (2005) 1.80
Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood (2008) 1.72
Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med (2011) 1.66
Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther (2009) 1.61
Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther (2013) 1.54
Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther (2011) 1.53
Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A (2009) 1.53
Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol (2007) 1.52
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther (2010) 1.51
Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol (2008) 1.50
Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol (2006) 1.43
Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol (2010) 1.42
Expression and function of NPSR1/GPRA in the lung before and after induction of asthma-like disease. Am J Physiol Lung Cell Mol Physiol (2006) 1.37
Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther (2009) 1.28
Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. J Virol (2003) 1.24
Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther (2010) 1.24
Long-term follow-up after gene therapy for canavan disease. Sci Transl Med (2012) 1.22
Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol (2010) 1.21
Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology (2012) 1.21
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther (2005) 1.19
Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca2+ release channel by NADPH oxidase 4. Proc Natl Acad Sci U S A (2011) 1.19
Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol (2012) 1.19
Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther (2009) 1.18
The next step in gene delivery: molecular engineering of adeno-associated virus serotypes. J Mol Cell Cardiol (2010) 1.17
Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol Ther (2010) 1.16
Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther (2012) 1.16
Effects of adeno-associated virus DNA hairpin structure on recombination. J Virol (2005) 1.15
Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc Natl Acad Sci U S A (2011) 1.14
Secretion of extracellular superoxide dismutase from muscle transduced with recombinant adenovirus inhibits the growth of B16 melanomas in mice. Mol Cancer Res (2003) 1.14
Self-complementary AAV2.5-BMP2-coated femoral allografts mediated superior bone healing versus live autografts in mice with equivalent biomechanics to unfractured femur. Mol Ther (2011) 1.10
Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther (2004) 1.09
Plac8 is an inducer of C/EBPβ required for brown fat differentiation, thermoregulation, and control of body weight. Cell Metab (2011) 1.05
Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat. Transplantation (2003) 1.05
Ocular gene transfer with self-complementary AAV vectors. Invest Ophthalmol Vis Sci (2007) 1.04
Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol (2012) 1.04
Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol (2012) 1.04
Surface loop dynamics in adeno-associated virus capsid assembly. J Virol (2008) 1.04
Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol (2013) 1.01
Capsid antibodies to different adeno-associated virus serotypes bind common regions. J Virol (2013) 1.01
Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther (2013) 1.00
Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther (2008) 1.00
Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J Virol (2012) 0.99
Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv (2010) 0.98
Adeno-associated virus vectors for therapeutic gene transfer. Biotechniques (2003) 0.98
Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression. J Virol (2003) 0.98
Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J Virol (2009) 0.97
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther (2015) 0.97
The role of surfactant protein A in bleomycin-induced acute lung injury. Am J Respir Crit Care Med (2010) 0.94
Quantitative 3D tracing of gene-delivery viral vectors in human cells and animal tissues. Mol Ther (2011) 0.94
AAV recombineering with single strand oligonucleotides. PLoS One (2009) 0.94
Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol (2014) 0.93
Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. J Clin Invest (2013) 0.92
A novel loss-of-function mutation in Npr2 clarifies primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, Maroteaux type. Hum Mol Genet (2012) 0.92
Viral single-strand DNA induces p53-dependent apoptosis in human embryonic stem cells. PLoS One (2011) 0.90
Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector. Ther Deliv (2012) 0.89
Retracted Osteopontin and protein kinase C regulate PDLIM2 activation and STAT1 ubiquitination in LPS-treated murine macrophages. J Biol Chem (2010) 0.88
Analysis of the interaction between adeno-associated virus and heparan sulfate using atomic force microscopy. Glycobiology (2004) 0.88
Adeno-associated virus of a single-polarity DNA genome is capable of transduction in vivo. Mol Ther (2008) 0.88
Adeno-associated virus for the treatment of muscle diseases: toward clinical trials. Curr Opin Mol Ther (2010) 0.88
An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Hum Gene Ther (2013) 0.88
Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes. J Immunol (2011) 0.88
Adaptation in a mouse colony monoassociated with Escherichia coli K-12 for more than 1,000 days. Appl Environ Microbiol (2010) 0.87
Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production. Virology (2005) 0.87
AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis. PLoS Pathog (2011) 0.87
Identification and characterization of an adeno-associated virus integration site in CV-1 cells from the African green monkey. J Virol (2003) 0.87
AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Circ Heart Fail (2012) 0.87
VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Angiogenesis (2010) 0.85
The effect of surface demineralization of cortical bone allograft on the properties of recombinant adeno-associated virus coatings. Biomaterials (2008) 0.85
Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis. Mol Ther Nucleic Acids (2013) 0.85
Creating a novel origin of replication through modulating DNA-protein interfaces. PLoS One (2010) 0.84
AAV-6 mediated efficient transduction of mouse lower airways. Virology (2011) 0.84
Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo. J Virol (2013) 0.84
Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors. J Virol (2009) 0.84
β-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice. Diabetes (2013) 0.83
AAV does the shuffle. Nat Biotechnol (2006) 0.83
Proteomic analysis of the NOS2 interactome in human airway epithelial cells. Nitric Oxide (2013) 0.83
Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis. Infect Immun (2013) 0.82
Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors. J Virol (2013) 0.82
Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction. Hum Gene Ther (2012) 0.81
Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical. Hum Gene Ther (2013) 0.81
Rapid transgene expression in multiple precursor cell types of adult rat subventricular zone mediated by adeno-associated type 1 vectors. Hum Gene Ther (2012) 0.81
Promyelocytic leukemia protein is a cell-intrinsic factor inhibiting parvovirus DNA replication. J Virol (2013) 0.81
In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside. PLoS One (2013) 0.80